Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Income from Non-Controlling Interests (2016 - 2018)

Coherus Oncology (CHRS) has disclosed Income from Non-Controlling Interests for 5 consecutive years, with -$18000.0 as the latest value for Q3 2018.

  • Quarterly Income from Non-Controlling Interests fell 350.0% to -$18000.0 in Q3 2018 from the year-ago period, while the trailing twelve-month figure was -$18000.0 through Jun 2019, up 68.97% year-over-year, with the annual reading at -$70000.0 for FY2018, 39.66% up from the prior year.
  • Income from Non-Controlling Interests hit -$18000.0 in Q3 2018 for Coherus Oncology, up from -$47000.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $111000.0 in Q4 2014 to a low of -$224000.0 in Q2 2015.
  • Historically, Income from Non-Controlling Interests has averaged -$75500.0 across 5 years, with a median of -$56500.0 in 2017.
  • Biggest five-year swings in Income from Non-Controlling Interests: skyrocketed 95.79% in 2017 and later tumbled 350.0% in 2018.
  • Year by year, Income from Non-Controlling Interests stood at $111000.0 in 2014, then tumbled by 270.27% to -$189000.0 in 2015, then surged by 87.83% to -$23000.0 in 2016, then surged by 91.3% to -$2000.0 in 2017, then tumbled by 800.0% to -$18000.0 in 2018.
  • Business Quant data shows Income from Non-Controlling Interests for CHRS at -$18000.0 in Q3 2018, -$47000.0 in Q2 2018, and -$5000.0 in Q1 2018.